ArticleJournal of cardiothoracic surgery2026
Comparative study of the tumor-infiltrating lymphocytes before and after neoadjuvant chemoimmunotherapy in esophageal squamous cell carcinoma.
Article in Journal of cardiothoracic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
background
objectiveTo explore changes of tumor-infiltrating lymphocytes and the relationship with therapeutic effect before and after neoadjuvant chemoimmunotherapy in patients with esophageal squamous cell carcinoma(ESCC).
methodThis study collected clinical data from 25 ESCC patients with neoadjuvant chemoimmunotherapy from November 2019 to June 2022 in our hospital. After the completion of the neoadjuvant treatment, Mckeown MIE surgery was performed. The pathological specimen before therapy and after surgery was collected. Immunohistochemical analysis was performed to obtain the tumor-infiltrating lymphocytes (TILs) infiltration of the tumor before and after treatment.
resultSeven (28%) patients achieved pathology complete response (pCR group) and 18 (72%) patients did not achieve pCR (non-pCR group). Compared with non-pCR group, the after treatment proportion of CD4 + TILs (P = 0.012) and the proportion of CD8 + TILs (P = 0.018) were significantly increased in pCR group; There was no significant change in the proportion of CD20 + TILs (Z = -1.933, P = 0.053). In pCR group, the proportion of CD4 + TILs (P = 0.047) and the proportion of CD8 + TILs (P = 0.036) were significantly increased after treatment; The proportion of CD20 + TILs (P = 0.111) did not change significantly. In non-pCR group, no significant changes were observed in proportions of CD4 + TILs (P = 0.729), CD8 + TILs (P = 0.712), and CD20 + TILs (P = 0.811) between before and after treatment.
conclusionFor ESCC patients who received neoadjuvant chemoimmunotherapy, patients with pCR had a more active immune response independent of pre-treatment PD-L1 expression levels, and the pre-treatment CD4 + TILs ratio may be one of the predictors of their survival.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.